TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

Two observational studies indicate GLP-1 receptor agonists may reduce complications after transcatheter aortic valve replacement (TAVR) and carotid artery stenting (CAS). Post-TAVR tirzepatide use was ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

A study showed that hospitals bought by private equity firms were admitting disproportionately healthier patients with heart failure -- whose outcomes did not correspond with their lower risk.

A risk model allowing cardiologists and their patients to share decision-making about undergoing surgery after transcatheter aortic valve replacement (TAVR) had received high marks for its accuracy in ...

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with transcatheter aortic valve replacement ...

At the annual meeting of the European Society of Cardiology (ESC), being held this weekend in Madrid, new cardiac care guidelines call for a more uniform, simplified and accessible approach to ...